Comparative Pharmacology
Head-to-head clinical analysis: DYNABAC versus ZMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYNABAC versus ZMAX.
DYNABAC vs ZMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dirithromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, specifically to the 23S rRNA, inhibiting peptide chain elongation by blocking the translocation step. It also interferes with the assembly of the 50S ribosomal subunit. This action is primarily bacteriostatic but can be bactericidal at higher concentrations.
Azithromycin, the active ingredient in ZMAX, is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
500 mg orally once daily or 250 mg orally twice daily; usual duration 5-14 days depending on infection
500 mg orally once daily, administered as a single dose on an empty stomach.
None Documented
None Documented
Terminal elimination half-life is 9–12 hours in adults with normal renal function; may extend to 20–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life: 68 hours (range 40-80 h); prolonged in hepatic impairment (up to 120 h) and elderly; supports once-weekly dosing.
Approximately 65% of a dose is excreted unchanged in the urine via glomerular filtration and tubular secretion; about 15% is excreted unchanged in the bile; fecal elimination accounts for <5%.
Renal: ~20% unchanged; fecal: ~50% as metabolites; biliary: ~30% as metabolites and parent drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic